Catalyst
Slingshot members are tracking this event:
Following preclinical trial, Halozyme Therapeutics (HALO) preparing to commence Phase 1 trial—testing combination of PEG PH20 and atezolizumab in treating pancreatic, gastric tumors among others—In the second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HALO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Occurred Source:
http://www.halozyme.com/investors/news-releases/news-release-details/2017/Initiation-Of-Clinical-Trial-Collaboration-Evaluating-Halozymes-PEGPH20-In-Combination-With-Anti-PDL1-Immunotherapy/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Ate Zo Lizumab, Pancreatic Cancer, Gastric Cancer, Pegph20
